ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

8.03
-0.23
( -2.78% )
Updated: 15:18:10

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.005.806.300.006.050.000.00 %00-
3.005.205.600.005.400.000.00 %00-
4.003.904.600.004.250.000.00 %00-
5.002.853.203.383.0250.000.00 %020-
6.002.052.803.032.4250.000.00 %01-
7.001.301.902.181.600.000.00 %02-
8.000.851.100.900.9750.000.00 %090-
9.000.400.600.500.500.000.00 %0392-
10.000.150.300.250.225-0.04-13.79 %2027209:30:09
11.000.100.200.150.150.0550.00 %411009:57:37
12.000.050.100.100.0750.000.00 %1045711:00:43
13.000.100.100.100.100.000.00 %0123-
14.000.050.400.050.2250.000.00 %0347-
15.000.100.450.100.2750.000.00 %030-
16.000.180.350.180.2650.000.00 %0101-
17.000.050.400.050.2250.000.00 %0299-

Professional-Grade Tools, for Individual Investors.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.000.000.500.000.000.000.00 %00-
3.000.000.500.000.000.000.00 %00-
4.000.050.500.050.2750.000.00 %010-
5.000.050.500.050.2750.000.00 %020-
6.000.100.200.100.150.000.00 %0100-
7.000.150.350.200.250.000.00 %0369-
8.000.450.700.600.5750.000.00 %0280-
9.001.001.351.201.1750.000.00 %0116-
10.001.852.101.721.9750.000.00 %039-
11.002.503.302.202.900.000.00 %05-
12.003.504.003.603.750.000.00 %010-
13.004.405.200.004.800.000.00 %00-
14.005.306.200.005.750.000.00 %00-
15.006.607.400.007.000.000.00 %00-
16.007.608.400.008.000.000.00 %00-
17.008.608.900.008.750.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ONVOOrganovo Holdings Inc
$ 1.2389
(235.75%)
350.83M
WAFUWah Fu Education Group Ltd
$ 3.275
(82.96%)
121.06M
RETOReTo Eco Solutions Inc
$ 1.00
(69.49%)
69.7M
SLXNSilexion Therapeutics Corporation
$ 1.14
(52.00%)
84.87M
LVTXLAVA Therapeutics NV
$ 1.3927
(48.16%)
19.21M
YYAIConnexa Sports Technologies Inc
$ 0.7418
(-41.59%)
5.29M
RNAZTransCode Therapeutics Inc
$ 4.075
(-39.90%)
532.47k
SNDKSanDisk Corporation
$ 49.72
(-34.73%)
5.64M
ACONAclarion Inc
$ 3.21
(-31.12%)
335.42k
SXTCChina SXT Pharmaceuticals Inc
$ 4.64
(-30.95%)
1.08M
ONVOOrganovo Holdings Inc
$ 1.23
(233.33%)
350.83M
NVDANVIDIA Corporation
$ 128.52
(-1.35%)
211.08M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.195
(-18.09%)
147.13M
WAFUWah Fu Education Group Ltd
$ 3.2701
(82.69%)
121.06M
PLTRPalantir Technologies Inc
$ 87.35
(-3.67%)
114.67M

AVXL Discussion

View Posts
georgejjl georgejjl 11 minutes ago
Christopher U. Missling, PhD, MS, MBA, is the President and CEO of Anavex

https://www.anavex.com/about-us

GOD bless,
👍️0
boi568 boi568 20 minutes ago
What you are requesting is just play acting, so of course you didn't get the response you wanted.
👍️0
Investor2014 Investor2014 22 minutes ago
We are for the moment still a $8 stock thought, so smile now tomorrow may be worse.

Remember some people vehemently claimed at $15 that $AVXL would never drop below again.
👎️ 1 👺 1
BAR123 BAR123 24 minutes ago
The biggest issue I have with AVXL is that it has never received the respect it deserves. We saw one brief rise to $31 with no news, but despite having the best data in the industry, the stock didn’t move much. Every other CNS company that released decent news saw huge run-ups—every single one. Yes, they all eventually pulled back, but we never got that spike. Remember, even with the best data ever, no run. Why?

My theory is that Dr. Missling needs to be elevated to CEO, and a new president should be brought in. Why do you think we never got the run we deserve? Think back to when BIIB surged by $20 billion in market cap—we should have at least hit a $4 billion market cap. SAVA shot up to $120 per share, ANVS to $132, and AXSM to $130. Why not AVXL?

Who has the answer to this? I could accept a rise to $30 followed by a pullback to $20, but sitting here at $7.97 is crazy. Unless, of course, we’re not being believed, or maybe we’re being accumulated and the games are being played until we approach key milestones, like the first stop for Q&A, approval, or a partnership.

I understand that a buyback will never happen, and the executives won’t be purchasing shares—they never do. After most of them being on board for 5-10 years they have collected enough free shares. Just buy a little. All of them. But share purchases would signal to everyone that the company is in great shape and encourage patience. What do you think is behind the lack of a run-up for AVXL? Trust of Missling? Trouble with the data? No FDA love over the years?

Thanks in advance.
👎️ 1 👺 1
meds4life meds4life 39 minutes ago
At an annual investor meeting I asked staff ( including IR guy if I remember right ) to show confidence in our drug results by purchasing some significant amount of AVXL shares to show they're putting some skin in the game. Most unenthusiastic responses followed.
👎️ 1 👺 1
mike_dotcom mike_dotcom 44 minutes ago
What a disaster this POS has turned into. And I know it'll get worse. It ALWAYS does.
👎️ 1 👺 1
IhidfromtheX IhidfromtheX 53 minutes ago
When the tariff's were instituted in his first term, companies from overseas moved to creating their operations in the U.S.A. It took a year or longer so what makes you believe it is faster this time. The fat is being cut and Government saving will appear...It happens in the private sector all of the time and this time it's the bloated government sector.
👍️ 4 👎️ 1 👺 1 🤣 1
Investor2014 Investor2014 1 hour ago
Lol! Do you by any chance have a worst expected date for approval or rejection?
👎️ 1 👺 1
georgejjl georgejjl 1 hour ago
CORRECTION>>>>>Anavex Life Sciences (AVXL) Institutional Ownership

https://www.marketbeat.com/stocks/NASDAQ/AVXL/institutional-ownership/

Good luck and GOD bless,
👍️ 1
rx7171 rx7171 1 hour ago
Sigma-1 agonists continue to exhibit positive effects in additional pathologies.
Are they the new Aspirin?
👍️ 1
boi568 boi568 1 hour ago
Normally, that's true. But normally tariff wars aren't instigated and normally the government doesn't plan to fire up to hundreds of thousands of its workers; normally the federal government doesn't aggressively attack its own economy. Then things move much faster.

On the other hand, all this economic chaos should not affect this company's fundamentals, so I guess worrying about the larger picture could be considered optional here -- as long as we have FDA staff still available to work on our upcoming NDA.
👍️ 1
georgejjl georgejjl 1 hour ago
My best expectation is late July 2025 or early August 2025 for EMA approval of blarcamesine.

Good luck and GOD bless,
👍️0
georgejjl georgejjl 1 hour ago
Anavex Life Sciences (AVXL) Institutional Ownership

https://link.springer.com/article/10.1007/s00210-025-03851-3

Good luck and GOD bless,
👍️ 1
rx7171 rx7171 2 hours ago
The graphic clearly shows the 120 day clock stop as four months.
So the 210 “working days” are calendar days.

So 30 weeks at an absolute minimum. 7.5 months that makes mid July.
However too optimistic for me so maybe October.
👍️0
IhidfromtheX IhidfromtheX 2 hours ago
Changes in economic activity don't change in a month...They take a year or so to take hold...
👎️ 1 👺 1
rx7171 rx7171 2 hours ago
My best expectation is November.
👍️ 1
plexrec plexrec 2 hours ago
Hoskuld--"None of that makes any sense"--good post and agree--TGD is running the co. the best he knows how---Monday morning Quarterbacks aren't going to change his mind---some shareholders may not like it but it is what it is--our day will come !!!
👍️ 1
Hoskuld Hoskuld 2 hours ago
None of that makes any sense, BAR123. CM converts all his options to shares except those shares he needs to liquidate to cover transaction costs. Insider buys are NBD. And CM isn't going anywhere: 11 years of planning play out this year.

Short covering will happen when it happens. Generally that happens when material events make shorting unattractive. That is what we are all waiting for. Last year we sat around $4-$5 per share this year we sit at $8-$9 per share because MAA was filed and peer review was published and OLE results are good.

Buyback is not going to happen. The company sells shares regularly to keep capital on hand high enough to give them flexibility. They are not going to rebuy what they are selling

This is pre-revenue biotech: share are massively f***ed with until the game suddenly ends. That will happen soon.
👍️ 6
IhidfromtheX IhidfromtheX 3 hours ago
And the press is out there screaming; fear, fear, fear! AVXL and the rest pay the price!
👍️ 1
kund kund 4 hours ago
Jiong Ma is the Board Chair—I got confused with the president. Anyway, having a separate president won’t make a difference since he will still be the boss. However, since Ma joined, there have been visible changes in the company: A) new hires B) No new option grants to the clown since 2022—all his options were granted before that. Also, his most recent grant has milestones attached.
🎯 2 👍️ 3 👎️ 1 👺 1
LakeshoreLeo1953 LakeshoreLeo1953 4 hours ago
More of an "if the shoe fits..." for the dry powder crowd.

I am sure we will hear from the in @ 8.01 and out @ 8.45 yesterday seers!!!!
👎️ 1 👺 1
kund kund 4 hours ago
I thought Jiong Ma was the president of the company. There was a vote back in 2022/23 to separate responsibilities from TGD, but it looks like he is still the president. The Anavex website and 10-K filings still list him as president.

This company has become his personal playground. He operates with an iron fist, which is why Wall Street has no respect for him.
👍️ 1 👎️ 2 👺 1
Citrati Citrati 4 hours ago
I do not day trade AVXL. I trade trading shares around a core position.
I do day trade a limited pool of select ETF's and among a few high volatility stocks.
👍️0
oldmystic oldmystic 4 hours ago
Take a look at Tulsa
https://invst.ly/1950os
👍️0
Citrati Citrati 4 hours ago
Would be nice to nail that trap door shut. 🤔. We shall see. Nice charts.
👍️ 2
georgejjl georgejjl 5 hours ago
Next Monday Anavex Life Sciences’s will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in Boston, MA.

A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.

https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-45th-annual-td-cowen-health-care-conference

Good luck and GOD bless,
👍️0
oldmystic oldmystic 5 hours ago
oldmystic 02/07/25 8:42 AM
Post #482646 on Anavex Life Sciences Corp (AVXL)
A breakdown at 8.5 opens the door to 5.65: https://invst.ly/18t-mn
Axle Daily: https://invst.ly/1950dp
👍️ 1 👎️ 1 👺 1
LakeshoreLeo1953 LakeshoreLeo1953 5 hours ago
Day trading activity at present is a tough game to play.
While I am comfortable momentum trading, I do not have the
patience or inclination to watch the tape for 6.5 hours.

For now....have fun!!
👍️0
georgejjl georgejjl 5 hours ago
Think about Anavex 3-71 not just blarcamesine.

“...A drug that receives Breakthrough Therapy designation is eligible for the following:
All Fast Track designation features
Intensive guidance on an efficient drug development program, beginning as early as Phase 1
Organizational commitment involving senior managers
Breakthrough Therapy designation is requested by the drug company. If a sponsor has not requested breakthrough therapy designation, FDA may suggest that the sponsor consider submitting a request if: (1) after reviewing submitted data and information (including preliminary clinical evidence), the Agency thinks the drug development program may meet the criteria for Breakthrough Therapy designation and (2) the remaining drug development program can benefit from the designation.

Ideally, a Breakthrough Therapy designation request should be received by FDA no later than the end-of-phase-2 meetings if any of the features of the designation are to be obtained. Because the primary intent of Breakthrough Therapy designation is to develop evidence needed to support approval as efficiently as possible, FDA does not anticipate that Breakthrough Therapy designation requests will be made after the submission of an original BLA or NDA or a supplement. FDA will respond to Breakthrough Therapy designation requests within sixty days of receipt of the request….”

https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

Good luck and GOD bless,
👍️ 2
Citrati Citrati 5 hours ago
Going to be tough for AVXL to gain much traction while XBI (biotech sector) is getting smacked again so far today.
👍️ 2
BIOChecker4 BIOChecker4 5 hours ago
None of this is new. These topics have been discussed here for years. I don’t think any of these criticisms or suggestions would be new to Missling. Missling does not have any interest in anybody’s advice. He does what he wants and that’s it. He can’t even bother to work with a communications professional to improve his presentation skills. He’s making millions and is unaccountable to his board or to shareholders. He has a job for life. What, then, would be his motivation?

Most of the institutions that hold AVXL are index funds, not actively managed biotech funds. The heavy hitters in biotech are on the sidelines. Whether they don’t believe in the technology or don’t believe in Missling or both is a huge unanswered question. However, Missling has done little to give serious biotech investors comfort.

Nobody should expect Missling to do anything other than what he has been doing all along. After all, it’s worked for him. At this point, Blarcamesine will either be approved or not. That’s it.

If some people are smart enough to make money trading AVXL, good for them.
👍️ 1 👎️ 2 👺 1 😬 1
BAR123 BAR123 5 hours ago
Our investment group has a contact within the company who communicates regularly with the Investor Relations team. She keeps us updated on all correspondence and calls she has with the IR team. There are a number of actions the company could take to curb short-selling, protect the stock price, and make raising funds at a higher valuation more achievable. We’ve seen steady but slow growth from institutional investors, and yes, the shorts continue to grow as well. I’ve heard repeatedly that short covering will be significant once the Peer Review is out, or when the OLE data is released, or when the EMA accepts our application, or when the FDA allows us to apply for approval—but remember, they haven’t even met with the FDA yet. When was the data released? Quite a while ago.

Our group has suggested that the company executives make a small purchase of shares on the open market—5,000 to 10,000 shares each. This would send a clear message. We understand that using corporate funds for a share buyback may not be the best option, but consider this: a $2 million buyback at $8 per share would buy back 250,000 shares. That, too, would send a message.

Is Missling the issue? Most would agree that he hasn’t met his commitments over the years, and this remains an ongoing issue. Did he mishandle the Rett trial? Probably. Did he mishandle the release of the Alzheimer's data? Yes. Does he have Wall Street’s support? It certainly doesn’t look that way.

We’re not necessarily suggesting he leave the company, but perhaps it’s time to bring someone in who has strong connections on Wall Street to take on the role of President while keeping him as CEO. Yes, we are a small company, but if he is the reason Wall Street isn’t fully backing us, this needs to be addressed. If we truly believe our drug has the potential to become the largest drug in history, we should be able to attract a strong president.

Apologies for another rant so soon, but there are clear steps that can be taken to protect shareholders and enhance the company’s prospects from both a management and financial perspective.
👍️ 5 👎️ 5 👺 1
Investor2014 Investor2014 6 hours ago
70% is more realistic than >83% chance of approval - all we can do it wait and maybe trade a bit of $AVXL in between now and Feb'ish 2026.
👍️ 2
hnbadger1 hnbadger1 7 hours ago
Grok 3 (Deepsearch) gives us a 70% chance of approval by EMA in
2025.
“ Conclusion
In conclusion, blarcamesine has a strong case for EMA approval in 2025, with a 70% estimated probability, driven by significant cognitive benefits, supportive biomarker data, and a favorable safety profile. The missed functional endpoint introduces risk, but the overall data package and regulatory flexibility for Alzheimer's treatments, especially given the challenges with ADCS-ADL in early stages, suggest a likely approval within the year, pending the review's outcome. The user's belief that both the EMA and FDA may de-emphasize ADCS-ADL is supported by research on its sensitivity, and potential alignment in regulatory approaches could further favor approval.”

Thanks Bio Friend on Stock Twiitz
👍️ 4
plexrec plexrec 8 hours ago
Bio---this should answer some of your questions--from Stocktwits board:
dnfrs
Yesterday 4:59 PM

$AVXL
FACT: Institutions have been buying.(over 40% now)
FACT: The JPAD peer reviewed article had 58 knowledgeable scientists sign it.
FACT: The OLE data was very positive. More to come.
FACT: EMA accepted the blarcamesine application (over 90% are approved)
FACT: In a few months Anavex 3-71 phase 2 Schizophrenia data will come.
FACT: EMA results by end of 2025
FACT: Submissions in UK, Canada and Australia expected by end 2025.
FACT: The general market is rocky.
FACT: Nothing Anavex can do about the general market.
FACT: Nothing Anavex can do about Institutions holding down stock to buy.
FACT: Many good biotechs are down.
But a lot of good news has come and a lot is coming.
I don't know a better stock to buy and hold!

1


29
👍️ 2 👎️ 1
Investor2014 Investor2014 13 hours ago
So even in oncology evaluations the vast majority of MAAs have 2 clocks stops, a few more than 2 and only 1 had just 1 clock stop.

I note that the review you posted refers to Median calendar days! In other words depending on the specific MAA and circumstances the evaluation time varies.

Note also that the review is specifically on oncology, an indication viewed as time critical.

Would interesting if a similar breakdown has been done for CNS indications.
👍️0
Investor2014 Investor2014 13 hours ago
I believe active days can effectively be and often is a much longer calendar day period. There are many external activities and pauses in the overall EMA process, where EMA staff is not actively involved in a particular evaluation.

The clock stops being two such non-active periods, where EMA is waiting on the sponsor’s answers to an LoQ or perhaps the assigned EMA staff are working on other MAA’s etc. within their capacity and priorities.

The EMA has defined that altogether 210 of their active days are set aside to complete each MAA evaluation.
👍️0
Guzzi62 Guzzi62 14 hours ago
Here is the timeline for cancer treatment products in PDF:

https://www.ispor.org/docs/default-source/euro2024/isporeurope24cervelobouzohpr86poster144868-pdf.pdf?sfvrsn=ebd2a543_0
👍️ 2
Steady_T Steady_T 15 hours ago
There is a difference of opinion on the board as to the 210 day being calendar days or active days. To me active days are defined as Monday through Friday less holidays.

I am of the active days opinion. There are others here that think it is calendar days.

This is what the EMA says. You can interpret it as you wish since it is not very clear.

The evaluation of medicines, step-by-step
The assessment of a marketing authorisation application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is the time spent by EMA experts to evaluate the evidence provided by the applicant in support of a marketing authorisation application./quote]

https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/evaluation-medicines-step-step
👍️ 1
skitahoe skitahoe 15 hours ago
I had expected the same thing from NWBO's filing in the UK, both have essentially the same time tables. Unfortunately we're now nearly 14 months from our submission, a few less from full validation, and still expecting the approval any day.

All I'm saying is these regulators do run behind, and still put at least some of the blame on Covid 19. I hope we do better with the European people, the fact that they asked the company to apply could be a big advantage. I'm just saying don't be too disappointed if it's late in 2025 or even early 2026.

Gary
👍️ 6
dia76ca dia76ca 16 hours ago
"The entire marketing authorization evaluation process usually takes 210 days." (calender days)
If the blarcamesine application follows the "usual" amount of time there could be EMA approval some time in July.
Or it could come earlier or later...maybe a month either way.
Is that how most posters see it?
👍️ 2
Citrati Citrati 16 hours ago
Shouldn't take too long for todays daily chart hammer candle close and the rising green 100period to resolve if this level support holds or not.
Extended the box in case the resolution drags out. 4ema still stuck negatively stacked under 8 and 13 ema's and price battling 100period.

https://investorshub.advfn.com/uimage/uploads/2025/2/24/rnriyScreen_Shot_2025-02-24_at_9.00.58_PM.png
👍️ 4
bb8675309 bb8675309 17 hours ago
Or a criminal syndicate. Whatever U want to call it.
👍️ 4
kund kund 17 hours ago
Another cabal theory. The biggest cabal is none other than TGD—every time he opens his mouth, the stock tanks. He might have even asked his friends at Maxim to short it so he can get cheap options.
👎️ 2 👺 1
bas2020 bas2020 18 hours ago
The answer is simple... the price is controlled by the WS mob: HFs/MMs that work to manipulate the price of many stocks to maximize profits via created volatility. At this point with AVXL, leading up to approval, they and their institution buddies, will continue to manipulate and suppress the SP in order to shake loose shares and allow themselves to accumulate on the cheap. Their mission is to create a counter intuitive "reality" that creates FUD in retail holders' minds, causing them to sell.
To be a successful trader, one has to anticipate their moves and trade accordingly. Otherwise, one just needs to hold and accumulate lower.
👍️ 15 👏 5
kspar1 kspar1 18 hours ago
Nailed. Dang, it looked so right coming out my fingers...
👍️0
Hoskuld Hoskuld 20 hours ago
BAR123, no company can answer questions about share price - they are not in control of share price. And there are analysts with $40+ share price targets.

Squeaking is not going to get it done. They need to execute. And maybe they are doing so now. They filed the MAA, they expanded the 3-71 P2, and they are about to launch a properly sized trial for PD.
👍️ 5
kund kund 20 hours ago
There is no new trial starting—Buffoon misspoke about the PD trial at JPM. Most of the time, he doesn’t even understand what he’s talking about. At JPM, he couldn't clearly articulate the company's achievements in simple words; EMA submission and peer review, he fumbled, struggling to find the words to complete his sentence. All PRs has some or other problem, no clarity is the biggest issue with his management style. The market has zero trust in his leadership, which is clearly reflected in the share price.
👎️ 2 👺 2
crescentmotor crescentmotor 20 hours ago
Missling's a veteran of IMGN and probably learned his sense of timing from them.

Yes--I bought my first IMGN shares around 2000. Indeed, I had forgotten about "NOOS" being substituted for "soon" when applied to Missling's timelines he provided investors. Unbelievable that some 25 years later, Missling still underperforms when it comes to investor guidance. Gosh Gary, we've been playing this stock market game a long time.
👎️ 2
boi568 boi568 20 hours ago
Anavex does not control all the elements of timing, and if that one element that I think has gone missing, I don't see how Missling could say anything that would improve the situation.
👍️ 1 👎️ 1